Status:
COMPLETED
A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma
Lead Sponsor:
Pharmacyclics LLC.
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of the study is to determine if the drug motexafin gadolinium will be an effective treatment for patients who have relapsed or refractory multiple myeloma.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Relapsed or Refractory Multiple Myeloma
- ≥ 18 years old
- Able to provide consent for participation
- ECOG status 0-2
- Lab values:
- ANC ≥ 1,000/µL
- WBC count ≥ 2.0/µL
- Hemoglobin ≥ 8.0 g/dL
- Platelet count ≥ 50,000/µL
- AST and ALT ≤ 2 x ULN
- Total Bilirubin ≤ 2 x ULN
- Creatinine ≤ 2.0 mg/dL
- and
- Not pregnant or lactating
Exclusion
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00096837
Last Update
June 8 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Robert H. Lurie Comprehensive Cancer Center
Chicago, Illinois, United States, 60611